Northeast Georgia Health System adopts Artrya’s AI platform, expanding access to preventive, point-of-care heart disease assessment.
Heart disease remains the world’s biggest killer, yet the tools used to diagnose it haven’t changed much in 50 years. That’s the core problem that Artrya says it’s trying to fix. With its newest commercial deal in the United States, the company is one step closer to making earlier, faster and more preventive heart disease assessment part of routine clinical care.
The Perth-based medtech company announced that Northeast Georgia Health System (NGHS) has signed a commercial agreement to use its Salix cloud-based AI platform across its network. The deal marks Artrya’s second commercial order in the US and signals growing momentum for AI-enabled cardiovascular diagnostics in real-world settings [1].
NGHS, which oversees five hospitals, outpatient centers and the Georgia Heart Institute’s physician practices, will introduce Salix into its workflow for patients with suspected or confirmed coronary artery disease (CAD) undergoing CT angiography. That’s a significant move: the network manages more than 100,000 cardiovascular patients each year.
What makes Salix different is its prevention-first approach. Rather than detecting blockages only once they become severe, the platform identifies coronary plaque features and blood flow issues earlier and more precisely. Using machine learning, Salix analyzes CT data in real time, providing clinicians with faster interpretations and reducing variability between readers.
Georgia Heart Institute chief cardiology officer Dr Mudassar Ahmed said Salix offers a critical advantage in everyday practice.
“Through our work [with Artrya] during the past two years, we have seen that Salix can bring a new dimension to our practice by supporting earlier identification of risk and enabling more proactive treatment strategies,” he said.
Instead of waiting for symptoms or emergencies, Ahmed says Salix helps clinicians spot early warning signs of CAD – giving patients more time and more options to intervene.
The agreement will license Salix as a SaaS platform with a fixed monthly subscription over a 36-month term, with a minimum value of US$300,000. Once Salix’s coronary plaque and coronary flow modules receive full FDA clearance, the system will also generate additional fee-per-scan revenue for Artrya.
To ensure a smooth rollout, Artrya’s Atlanta team will handle onboarding, training, technical integration, and clinician engagement. The goal is to embed Salix directly into the systems clinicians already use daily – from picture archiving (PACS) to electronic medical records – without adding steps or friction.
Artrya CEO John Konstantopoulos said the NGHS agreement is a milestone in the company’s US strategy.
“We remain on track to convert all three of our US foundation partners to commercial customers this year and our new Customer Success team is already playing a leading role in the integration and support of our technology,” he said.
The company frames the deal as both a commercial win and a validation of Salix’s clinical utility. It also builds on Artrya’s mission to change how the world diagnoses heart disease, shifting from reactive care to precision-based prevention.
Coronary artery disease is still the leading cause of death in developed countries. For decades, diagnostic practices have relied primarily on the same manual methods: interpreting CT scans by hand, assessing risk factors and waiting for symptoms to escalate. But CAD often advances silently, and many patients don’t receive meaningful intervention until it’s too late.
Artrya is betting that AI can help rewrite that script. By providing clinicians with consistent, high-resolution plaque analysis, without invasive procedures, Salix aims to shorten the time to diagnosis and expand access to prevention-focused care.
According to Georgia Heart Institute medical director Dr Zaid Said, integrating AI into cardiovascular workflows “reflects a commitment to advancing cardiovascular medicine and ensures patients across Georgia Heart Institute can benefit from faster, more accurate diagnoses and improved outcomes.”
It’s a reminder that prevention isn’t just about lifestyle guidance; it’s about giving clinicians the tools to intervene earlier, with more precision, for more people.
Artrya has positioned itself as a leader in AI-driven cardiac diagnostics. With two commercial US orders secured and more expected this year, the company is leaning hard into a future where earlier detection becomes the standard.
If Salix continues to gain traction, it may help shift heart disease care toward what the field has long needed: timely, data-driven prevention that saves lives before a crisis happens.
